FDA panel to review NicOx's anti-inflammatory naproxcinod
This article was originally published in Scrip
Executive Summary
A joint meeting of the US FDA's arthritis drugs advisory committee and the drug safety and risk management advisory committee has been scheduled for May 12th to review NicOx's anti-inflammatory agent naproxcinod for the treatment of osteoarthritis.